Review Article

Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers

Table 2

Pooled drug survival rates with number of patients/studies evaluated for ETA, ADA, and INF at different time points among the included studies (12 comparative studies evidence).

Biologic pretreatment statusIntervention6 m12 m18 m24 m36 m48 m60 m

Biologic-naive studiesADA83.9 (1556) 
74.4 (1339) 
67.7 (1339)  
63.6 (1339)  
57.6 (1339)  
47.2 (1093)  
47.5 (769)  
ETN84.5 (1280)  
82.1 (1064)  
74.6 (1064)  
71.5 (1064)  
64.6 (1048)  
58.5 (1117)  
52.2 (517)  
INF82.2 (2027)  
69.0 (1924)  
60.7 (1924)  
55.8 (1924)  
47.0 (1804)  
42.4 (1503)  
37.1 (1134)  

Overall comparative evidenceADA87.0 (3194)  
76.2 (3278)  
70.8 (2538)  
63.4 (3278)  
53.1 (3278)  
47.2 (1093)  
47.5 (769)  
ETN88.1 (3333) 
80.1 (3062)  
75.1 (2470)  
67.6 (3062)  
57.2 (3046)  
51.0 (1636)  
52.2 (517)  
INF84.3 (3356 
70.9 (3318)  
64.1 (2881)  
55.6 (3318)  
42.9 (3198)  
39.0 (1865) 
37.1 (1134)  

ADA: adalimumab; ETN: etanercept; INF: infliximab; represents the number of studies involved.